Tango Therapeutics, Inc.

Tango Therapeutics, Inc. is a U.S.-based precision oncology company focused on discovering and developing targeted cancer therapies for genetically defined patient populations. Its pipeline centers on small-molecule drug candidates designed to selectively attack cancer cells with specific genetic alterations while sparing normal cells.

−174,7 %

−162,9 %

+48,3 %

16.32

16.32

— Tango Therapeutics, Inc.
%
Clinical-stage oncology programs80% Drug candidates in human clinical development for genetically defined cancers.
Collaboration revenue20% Revenue recognized from partnered research and licensing arrangements.
Target discovery platform0% Internal discovery capabilities used to identify disease-relevant oncology targets.

Tango Therapeutics does not sell commercial products today; its economic counterparties are pharmaceutical...

  • Pharmaceutical collaboration partnersprimary

    Buy access to discovery, research, and licensing rights in oncology programs.

  • Future oncology treatment providerssecondary

    Hospitals, cancer centers, and oncologists that would use approved therapies.

  • Payers and reimbursement decision-makerssecondary

    Assess clinical value and coverage for any approved cancer medicines.

  • Research and translational science partnersemerging

    Support target validation, biomarker work, and early-stage development.

The company is headquartered in the United States and conducts its core research and development activities from...

  • •Headquartered in the United States
  • •Boston, Massachusetts is a key office and laboratory location
  • •Clinical and regulatory activity is centered in the U.S. and other major markets
  • •Third-party API and drug-product supply includes China exposure
  • •Future commercialization would likely expand into U.S. and ex-U.S. markets

Tango Therapeutics is focused on advancing genetically targeted oncology programs through clinical proof-of-concept and...

01
Advance vopimetostat and TNG456 in clinical developmentshort-term

Clinical validation is the main path to value creation for a pre-commercial oncology company.

02
Differentiate through genetically defined patient selectionmedium-term

Targeting MTAP-deleted tumors can improve selectivity and clinical relevance.

03
Expand combination and CNS opportunitiesmedium-term

Combination regimens and brain-penetrant assets broaden the addressable oncology market.

04
Preserve access to external funding and partnershipsshort-term

The company depends on collaboration revenue and capital markets to finance development.

The company faces the typical risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk,...

high

Clinical development failure

Pipeline value depends on demonstrating safety and efficacy in human trials.

Scope
vopimetostat, TNG456, TNG260
Materiality
high
high

Manufacturing and supply concentration

API and drug product rely on a small number of third-party suppliers.

Scope
Clinical trial supply and future commercial supply
Materiality
high
high

Capital dependence

The company must fund long-duration R&D before product revenue exists.

Scope
Equity, debt, and collaboration financing
Materiality
high
medium

China-related supply chain exposure

One CDMO is located in China, creating geopolitical and logistics risk.

Scope
API and drug product sourcing
Materiality
high
medium

Competitive pressure in oncology

Other companies are developing PRMT5 and related precision oncology programs.

Scope
PRMT5 inhibitor market and broader oncology pipeline
Materiality
high
medium

Pricing and reimbursement risk

Future approved therapies may face coverage limits and pricing pressure.

Scope
U.S. and ex-U.S. commercialization
Materiality
medium
Revenue recognition for collaborations
Affects timing and volatility of reported revenue
Deferred revenue
Can materially shift revenue between quarters and years
Contingent milestone and royalty obligations
Affects future expense recognition and cash outflows
Lease accounting
Affects balance sheet leverage and operating expense presentation
Clinical trial and manufacturing accruals
Can affect R&D expense timing and comparability

Relay Therapeutics, Inc.

RLAY · Biological Products, (No Diagnostic Substances)

Marker Therapeutics, Inc.

MRKR · Pharmaceutical Preparations

Gain Therapeutics, Inc.

GANX · Pharmaceutical Preparations

Compass Therapeutics, Inc.

CMPX · Biological Products, (No Diagnostic Substances)

SANGAMO THERAPEUTICS, INC

SGMOQ · Biological Products, (No Diagnostic Substances)

CERO THERAPEUTICS HOLDINGS, INC.

CERO · Biological Products, (No Diagnostic Substances)

: 29/04/2026